(Q34335067)

English

In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

0 references

placebo-controlled trial

1 reference

based on heuristic

inferred from title

object named as

Alireza Rahimi

6

0 references

Mohammad Haghighi

object named as

Mohammad Haghighi

1

0 references

Leila Jahangard

object named as

Leila Jahangard

2

0 references

object named as

Serge Brand

9

0 references

Edith Holsboer-Trachsler

8

object named as

Edith Holsboer-Trachsler

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

4

object named as

Hafez Bajoghli

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

author name string

Hamid Mohammad-Beigi

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Hassan Hafezian

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Hamid Afshar

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

23 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

228

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

633-640

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Glutamatergic dysfunction in OCD.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Treatment of obsessive compulsive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

The Yale-Brown Obsessive Compulsive Scale. II. Validity

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

A family study of obsessive-compulsive disorder with pediatric probands.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

A review and meta-analysis of the genetic epidemiology of anxiety disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Memantine as an augmenting agent for severe pediatric OCD.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

The epidemiology of obsessive-compulsive disorder in five US communities.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Symptom stability in adult obsessive-compulsive disorder: data from a naturalistic two-year follow-up study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Memantine augmentation for refractory obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Memantine for treatment-resistant OCD.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

A.E. Bennett Research Award. Toward a neurodevelopmental model of of obsessive--compulsive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Brain-behavior relationships in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

A single-blinded case-control study of memantine in severe obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Neurobiology of obsessive-compulsive disorder: insights into neural circuitry dysfunction through mouse genetics

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3067-Z

21 January 2018

Twin studies on obsessive-compulsive disorder: a review

1 reference

https://pubmed.ncbi.nlm.nih.gov/23525525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23525525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine

1 reference

https://pubmed.ncbi.nlm.nih.gov/23525525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/23525525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/23525525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Obsessive-compulsive disorder-related disorders: the role of selective serotonergic reuptake inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23525525

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00213-013-3067-Z

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34335067&oldid=2196518504"